Iowa State University
The Nanovaccine Institute, established at Iowa State University in 2017, is a national transdisciplinary research consortium focused on advancing nano-based technologies to treat and prevent diseases. The institute aims to revolutionize public health outcomes through the design and promotion of nano-based vaccines and therapeutics.
Industries
N/A
Nr. of Employees
small (1-50)
Iowa State University
5001 ATRB, 2213 Pammel Drive, Ames, IA 50011-1101
Products
Universal influenza intranasal powder nanovaccine (preclinical)
A nanoparticle-based intranasal powder vaccine candidate intended to provide broad protection against influenza strains, designed for single-dose administration, ambient-temperature stability, and needle-free delivery.
Amphiphilic polyanhydride nanomedicines for antimicrobial-resistant pathogens (preclinical)
Nanoparticle formulations designed to deliver antimicrobials across protective barriers of parasites and resistant bacteria to improve efficacy and reduce systemic side effects.
Monoclonal antibody-based quantitative enzyme immunoassay for α-synuclein (research assay)
A quantitative enzyme immunoassay developed with specific monoclonal antibodies to detect pathological aggregates of α-synuclein for early diagnosis and research in neurodegenerative disease.
Universal influenza intranasal powder nanovaccine (preclinical)
A nanoparticle-based intranasal powder vaccine candidate intended to provide broad protection against influenza strains, designed for single-dose administration, ambient-temperature stability, and needle-free delivery.
Amphiphilic polyanhydride nanomedicines for antimicrobial-resistant pathogens (preclinical)
Nanoparticle formulations designed to deliver antimicrobials across protective barriers of parasites and resistant bacteria to improve efficacy and reduce systemic side effects.
Monoclonal antibody-based quantitative enzyme immunoassay for α-synuclein (research assay)
A quantitative enzyme immunoassay developed with specific monoclonal antibodies to detect pathological aggregates of α-synuclein for early diagnosis and research in neurodegenerative disease.
Services
Bench-to-bedside translational support including preclinical study design, pre-IND planning, and coordination with clinical and regulatory partners.
Coordination of multi-institution collaborations, industry engagement, and support for patenting and licensing pathways toward commercialization.
Organization of an annual scientific conference, production of a podcast series, and distribution of quarterly newsletters to share research updates and foster community engagement.
Institutional core facilities and research staff that support nanoparticle design, formulation, and preclinical testing workflows.
Bench-to-bedside translational support including preclinical study design, pre-IND planning, and coordination with clinical and regulatory partners.
Coordination of multi-institution collaborations, industry engagement, and support for patenting and licensing pathways toward commercialization.
Organization of an annual scientific conference, production of a podcast series, and distribution of quarterly newsletters to share research updates and foster community engagement.
Institutional core facilities and research staff that support nanoparticle design, formulation, and preclinical testing workflows.
Expertise Areas
- Immunology
- Nanotechnology
- Materials science
- Microbiology
Key Technologies
- Polymeric nanoparticles
- Spray-drying nanoparticle manufacture
- Intranasal powder vaccine formulation
- Mucosal vaccine delivery